Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: C. K. Humphries who wrote (6138)	1/17/1999 12:35:00 PM
From: Tokyo VD	Read Replies (1) \| Respond to of 7041

CK, I'm not sure your last statement is true. While I agree that the formulation (molecular structure) hasn't changed, I believe the patent covers the delivery method. The claim in the Lowry patent was based on the ability to demonstrate a shift in the curve for peak plasma concentration. I don't know about confirmatory studies, but the data definitely demonstrated a quicker rate to peak concentration. Nevertheless, the accompanying patient study in the patent (n=8?) to confirm efficacy was comical to me. Tokyo